Q&A with CEO Lisa Quarterman about VativoRx’s efforts to reduce opioid misuse and abuse

Q&A with CEO Lisa Quarterman about VativoRx’s efforts to reduce opioid misuse and abuse

What can the PBM industry do to help solve this crisis?

PBMs, pharmacists, and physicians all need to work together and take an active role in helping to curb this epidemic. VativoRx’s Opioid Risk Management Program works to coordinate care by identifying patterns of potential overuse or misuse and sharing profile reports with pharmacies and physicians to intervene when warranted.

What specific actions has VativoRx taken to help solve this crisis?

We offer our clients the Opioid Risk Management Program, which includes many additional components such as a tighter refill window, prior authorization, quantity limits, and other custom edits. Clients can customize this program depending on their unique needs and tolerance for disruption.

What do we do about patients with severe pain who truly need opioids?

There are many legitimate uses for high-frequency narcotic use, that’s why VativoRx clinically reviews cases exceeding certain thresholds to verify medical necessity and coordinate care.

What is the role of the HCP in helping to solve this crisis?

Health care providers need to take a proactive role in helping control the opioid crisis by implementing more stringent plan designs and programs that monitor and limit the dispensing of opioid prescriptions such as prior authorizations, quantity limits, and higher-utilizer intervention programs.

VativoRx Joins MHA: A New Chapter Begins

The world of healthcare is dynamic, continuously evolving with new challenges and opportunities. At VativoRx, we’ve always believed in the power of innovation, collaboration, and dedication to ensure that we provide the best rebate management solutions in the industry. Today, we’re thrilled to announce our latest milestone: VativoRx is now an official associate member of the Michigan Health & Hospital Association (MHA)!

Read More »

Unveiling the Future: Navigating the Evolving Landscape of 340B Rebates.

The 340B Drug Pricing Program, established in 1992, has been a crucial component of the healthcare system, dedicated to assisting eligible healthcare organizations in serving vulnerable patient populations by granting them access to discounted drugs. At the heart of this program are the 340B rebates, which enable qualifying entities such as safety-net hospitals, community health centers, and other eligible providers to acquire medications at significantly reduced prices.

Read More »
Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »

Biosimilars — Similar But Not Identical

You may have never heard of biosimilar drugs and that’s probably because they are not commonly prescribed in the United States even though they have been around for over 20 years. So, what are biosimilar drugs? A biosimilar drug is no different in terms of safety and effectiveness than a biologic product, also known as a reference product, and while highly similar it is not identical.

Read More »

Lower Cost Prescription Drugs from Canada, Is It Legal?

In the early 2000s, the FDA set up guidelines in the Regulatory Procedures Manual (RPM) that permitted prescription drugs to be imported from other countries if the patient met very strict guidelines. Just stating that the patient needed the drug due to cost savings was not a justification to obtain the drug.

Read More »